Interferon Gamma-1B
Metastatic Synovial Sarcoma
National Cancer Institute (NCI)protein_peptidePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Metastatic Synovial Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazemetostat Epizyme, Inc. | Phase 2 | BB |
Cyclophosphamide Zelluna Immunotherapy AS | Phase 2 | BB |
Pembrolizumab Valo Therapeutics Oy | Phase 2 | B |
Cixutumumab National Cancer Institute (NCI) | Phase 2 | B |
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
View all 36 →
Same molecule, other indications
Interferon Gamma-1B is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →